CBIO

Catalyst Biosciences, Inc. [CBIO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CBIO Stock Summary

In the News

CBIO Financial details

Company Rating
-
Market Cap
19.42M
Income
-44.24M
Revenue
-794K
Book val./share
-
Cash/share
-
Dividend
0.24
Dividend %
46.94%
Employees
7
Optionable
No
Shortable
Yes
Earnings
26 Oct 2023
P/E
-0.44
Forward P/E
-
PEG
0.08
P/S
-24.46
P/B
5.52
P/C
-
P/FCF
-1.45
Quick Ratio
1.92
Current Ratio
2.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.38
EPS next Y
-
EPS next Q
-
EPS this Y
-90.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-37.29%
Revenue last 5Y
165.66%
Revenue Q/Q
-
EPS Q/Q
-36.54%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-444%
ROE
244%
ROC
-5.41%
Gross Margin
201%
Oper. Margin
5575%
Profit Margin
5572%
Payout
-131%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.1887-8.693999
52W High
-
52W Low
-
RSI
-
Rel Volume
1.05
Avg Volume
437.27K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.29
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

CBIO Financial Performance

CBIO Dividend History

CBIO Frequently Asked Questions

What is Catalyst Biosciences, Inc. stock symbol ?

Catalyst Biosciences, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol CBIO

What is Catalyst Biosciences, Inc. stock quote today ?

Catalyst Biosciences, Inc. stock price is $- today.

Is Catalyst Biosciences, Inc. stock public?

Yes, Catalyst Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
BRH.DE
GOOG
JPM
LLY.DE
0YXG.L
Same Sector
1731.TW
SAN.PA
1110.HK
SHC
DIGN.ST
Check Those
XMI.TO
GALLISPAT.NS
0LK3.L
CNY
9788.T
Similar Market Cap
XPHI.L
8623.HK
FALC
SLGL
FHQ.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 437.27K
  • Market Capitalization 19.42M
  • Employee 7
  • CEO Dr. Nassim Usman Ph.D.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2006-04-12
  • Website https://www.catalystbiosciences.com

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.